FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
RegulatoryapprovedLyrfigtuPositive
AI Analysis
Summary
The FDA approved Lyrfigtu (lirafugratinib), developed by Elevar Therapeutics, for treating cholangiocarcinoma with FGFR2 fusion or other rearrangement. This represents a regulatory approval for a targeted oncology treatment.
Outcome Details
FDA approval for cholangiocarcinoma with FGFR2 fusion or other rearrangement
Importance:8/10
Sentiment:
0.90
FDA approvaloncologycholangiocarcinomaFGFR2 fusionElevar Therapeutics
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 23, 2026 11:09 PM